Edge Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Edge Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-5,000	Closed	-$175K	–	554
2017 Q2	$175K	Buy	+5,000	New	+$163K	0.06%	136
2016 Q2	–	Sell	-500	Closed	-$10K	–	479
2016 Q1	$10K	Buy	+500	New	+$8.74K	﹤0.01%	285

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

TCP

Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Edge Wealth Management's SRPT Position: Q3 2017 in Review

Edge Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q3 2017, closing a stake of 5,000 shares — an estimated $175K sold.

Edge Wealth Management first reported a position in SRPT in Q1 2016 and held it in 2 quarters. The position peaked at $175K in Q2 2017. 233 funds tracked by Wall St. Rank hold SRPT as of Q3 2017.

Edge Wealth Management reported no remaining Sarepta Therapeutics position as of Q3 2017 after selling out during the quarter.
Edge Wealth Management sold 5,000 Sarepta Therapeutics shares in Q3 2017, an estimated $175K.
Edge Wealth Management first reported a position in Sarepta Therapeutics in Q1 2016 and held it in 2 quarters.
Edge Wealth Management's Sarepta Therapeutics position peaked at $175K in Q2 2017.
233 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2017.

Based on Edge Wealth Management's 13F filing for Q3 2017, filed 19 Oct 2017.